Asset Details
Do you wish to reserve the book?
In silico exploration of deep-sea fungal metabolites as inhibitor of Ebola and Marburg VP35 and VP40
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
In silico exploration of deep-sea fungal metabolites as inhibitor of Ebola and Marburg VP35 and VP40
Do you wish to request the book?
In silico exploration of deep-sea fungal metabolites as inhibitor of Ebola and Marburg VP35 and VP40
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
In silico exploration of deep-sea fungal metabolites as inhibitor of Ebola and Marburg VP35 and VP40
2024
Overview
VP30 and VP40 proteins of Ebola and Marburg viruses have been recognized as potential targets for antiviral drug development due to their essential roles in the viral lifecycle. Targeting these proteins could disrupt key stages of the viral replication process, inhibiting the viruses’ ability to propagate and cause disease. The current study aims to perform molecular docking and virtual screening on deep-sea fungal metabolites targeting Marburg virus VP40 Dimer, matrix protein VP40 from Ebola virus Sudan, Ebola VP35 Interferon Inhibitory Domain, and VP35 from Marburg virus. The top ten compounds for each protein target were chosen using the glide score. All the compounds obtained indicate a positive binding interaction. Furthermore, AdmetSAR was utilized to investigate the pharmacokinetics of the inhibitors chosen. Gliotoxin was used as a ligand with Marburg virus VP40 Dimer, Austinol with matrix protein VP40 from Ebola virus Sudan, Ozazino-cyclo-(2,3-dihydroxyl-trp-tyr) with Ebola VP35 Interferon Inhibitory Domain, and Dehydroaustinol with VP35 from Marburg virus. MD modeling and MMPBSA studies were used to provide a better understanding of binding behaviors. Pre-clinical experiments can assist validate our in-silico studies and assess whether the molecule can be employed as an anti-viral drug.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Antiviral Agents - chemistry
/ Antiviral Agents - pharmacology
/ Binding
/ Biological response modifiers
/ Deep sea
/ Dimers
/ Energy
/ Fungi
/ Genomes
/ Hemorrhagic Fever, Ebola - drug therapy
/ Hemorrhagic Fever, Ebola - virology
/ Humans
/ Ligands
/ Medicine and Health Sciences
/ Molecular Docking Simulation
/ Molecular Dynamics Simulation
/ Proteins
/ Viral Matrix Proteins - antagonists & inhibitors
/ Viral Matrix Proteins - chemistry
/ Viral Matrix Proteins - metabolism
/ Viral Regulatory and Accessory Proteins
/ Viruses
